If PCI with stenting is performed, how long should a P2Y12 inhibitor be continued?

If PCI with stenting is performed, how long should a P2Y12 inhibitor be continued?

• A. Continue for 6-12 months
• B. Continue for more than 12 months
• C. Continue for 3 months
• D. Do not use P2Y12 inhibitors after PCI

Answer: (B)

After PCI with a stent in the setting of acute coronary syndrome, ongoing dual antiplatelet therapy is essential to prevent stent thrombosis and recurrent ischemic events. This means continuing a P2Y12 inhibitor in addition to aspirin for at least 12 months. In patients with low bleeding risk and ongoing ischemic risk, extending the P2Y12 inhibitor beyond 12 months can provide extra protection, so the option of continuing for more than 12 months is the best choice. Shorter durations (like 3 months or 6–12 months) are generally not sufficient in this scenario, and stopping the P2Y12 inhibitor entirely after PCI would leave the stent at high risk for thrombosis.

After PCI with a stent in the setting of acute coronary syndrome, ongoing dual antiplatelet therapy is essential to prevent stent thrombosis and recurrent ischemic events. This means continuing a P2Y12 inhibitor in addition to aspirin for at least 12 months. In patients with low bleeding risk and ongoing ischemic risk, extending the P2Y12 inhibitor beyond 12 months can provide extra protection, so the option of continuing for more than 12 months is the best choice. Shorter durations (like 3 months or 6–12 months) are generally not sufficient in this scenario, and stopping the P2Y12 inhibitor entirely after PCI would leave the stent at high risk for thrombosis.